Genentech
Genentech articles from Informachine.Genentech rejects Roche’s $43.7-billion takeover offer as too low
13 Aug 2008
Biotechnology giant Genentech Inc today rejected a $43.7-billion takeover bid from its majority shareholder, Roche Holding AG, as too low, while saying it would be open to a higher proposal.
Stay ahead with Informachine News Trackers! Follow your selected sources, track business news with relevant keywords, and organize seamlessly using labels and bookmarks.
Get the business updates you need, fast, focused, and tailored just for you. Save time, stay informed, and never miss a beat!
Latest articles on Genentech from Informachine
Genentech and Breastcancer.Org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends
01 Oct 2026
More than 225,000 women in the U.S. are expected to be diagnosed with hormone receptor HR+, HER2- breast cancer this year, the most common form of the disease, representing approximately 70% of cases
Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions
01 Oct 2026
New real-world results for Vabysmo in wet AMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals
Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-Positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
01 Oct 2026
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus
Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
30 Sep 2026
The filing acceptance for fenebrutinib, an investigational BTK inhibitor, is based on data from the comprehensive clinical program, including the Phase III FENhance 1 and 2 RMS studies and the Phase III FENtrepid PPMS study.
Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon
29 Sep 2026
Discover the latest news about our company, our products, our policies, and our people.
Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)
28 Sep 2026
In the Phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential
Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity
28 Sep 2026
Discover the latest news about our company, our products, our policies, and our people.
Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center
28 Sep 2026
Discover the latest news about our company, our products, our policies, and our people.
Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study
28 Sep 2026
Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people wi
U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
28 Sep 2026
The filing acceptance is based on positive results from the Phase III METEOROID study, which showed that Enspryng provided consistent, clinically meaningful improvements for people living with MOGAD.
